Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.

NCT03718117 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03718117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03718117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 3, 2017
Completion date
July 1, 2020
Enrollment
73 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement or ros1 gene rearrangement, crizotinib, nsclc